Beyond TLR2, targeting TLR4 with small-molecule inhibitors or neutralizing mAbs has also shown anticancer efficacy, especially in chemically induced models of colitis-associated colon cancer.592 However, the translation of TLR4 inhibitors into clinical practice for cancer treatment has not yet succeeded. Here, TLR4 is linked to colitis.